Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491364 | 0.80 | BRD4 (0.61) | BRD4SMN1; SMN2SCN2AALDH1A1MAPT | |
| SCHEMBL16426224 | 0.76 | BRD4 (0.66) | BRD4SMN1; SMN2ALDH1A1 | |
| SCHEMBL15351887 | 0.76 | BRD4 (0.66) | BRD4SMN1; SMN2ALDH1A1 | |
| SCHEMBL957329 | 0.74 | SMN1; SMN2 (1.00) | BRD4SMN1; SMN2CDC7ALDH1A1MAPT | |
| SCHEMBL29678302 | 0.71 | TSHR (0.58) | SCN2AALDH1A1 | |
| SCHEMBL1263144 | 0.71 | TSHR (0.58) | SCN2AALDH1A1 | |
| SCHEMBL17336712 | 0.70 | SMN1; SMN2 (0.58) | BRD4SMN1; SMN2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL20472961 | 0.69 | MAOB (0.56) | SCN2AALDH1A1 | |
| SCHEMBL15352222 | 0.69 | SMN1; SMN2 (0.62) | BRD4SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28055593 | 0.69 | SCN2A (0.42) | SMN1; SMN2SCN2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379543-A2 | THIAZOLYL-BENZIMIDAZOLES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010121675-A2 | THIAZOLYL-BENZIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | BRD4 727/4885SMN1; SMN2 2260/4885SCN2A 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.